





+







-












_


+










+







 \perp







+













 \perp








F16._10B





DEFELL LEOSHED


BL6/GM + Hamster IgG

anti-CTLA4


BL6/GM + anti-CTLA4

Hamster IgG


days postchallenge



days postchallenge



% surviving mice



anti-CTLA4 (n=9)

anti-CTLA4 + F10/GM (n=13)

Hamster IgG + F10/GM (n=10)

Hamster IgG (n=10)






FIGURE 16A



(*= χ 2 vs. ctrl lg/no vaccine, treated at same age-14 weeks)




*=vs. ctrl lg/no vaccine

**=vs. ctrl lg/GMTRAMP-C1/C2

***=vs. anti-CTLA-4/no vaccine

Statistically Significant Using Fisher, Scheffe, Bonferroni/Dunn Tests



*=vs. ctrl lg/no vaccine and ctrl lg/GMTC1/2

FIGURE 173

IFN-γ Production after Peptide Stimulation In Vitro




FIGURE 18

CTLA-4 Blockade Is Required for Delaying B16 Melanoma Growth In Immunized Mice Tumor Size (mm³) 200-400-500 300-100-Mgp100/DC+560 B16+9H10 Mgp10/DC+9H10 DC+560 B16+560 DC only+9HIO

FIGURE

0

20

25

30